Cargando…

The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report

INTRODUCTION: Calcitonin (Ct) and carcinoembrional antigen (CEA) are widely used as tumor markers for the post-operative follow-up of patients with medullary thyroid carcinoma (MTC). In patients with elevated serum Ct and CEA their dynamics can be described by calculating the doubling time (DT) - th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gawlik, Tomasz, d'Amico, Andrea, Szpak-Ulczok, Sylwia, Skoczylas, Aleksander, Gubała, Elżbieta, Chorąży, Anna, Gorczewski, Kamil, Włoch, Jan, Jarząb, Barbara
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2987862/
https://www.ncbi.nlm.nih.gov/pubmed/21047422
http://dx.doi.org/10.1186/1756-6614-3-10
_version_ 1782192171624955904
author Gawlik, Tomasz
d'Amico, Andrea
Szpak-Ulczok, Sylwia
Skoczylas, Aleksander
Gubała, Elżbieta
Chorąży, Anna
Gorczewski, Kamil
Włoch, Jan
Jarząb, Barbara
author_facet Gawlik, Tomasz
d'Amico, Andrea
Szpak-Ulczok, Sylwia
Skoczylas, Aleksander
Gubała, Elżbieta
Chorąży, Anna
Gorczewski, Kamil
Włoch, Jan
Jarząb, Barbara
author_sort Gawlik, Tomasz
collection PubMed
description INTRODUCTION: Calcitonin (Ct) and carcinoembrional antigen (CEA) are widely used as tumor markers for the post-operative follow-up of patients with medullary thyroid carcinoma (MTC). In patients with elevated serum Ct and CEA their dynamics can be described by calculating the doubling time (DT) - the time, they need to double the serum concentration. Previous reports concluded that the Ct and CEA DT have prognostic value in MTC patients. PATIENTS AND METHODS: We retrospectively analyzed data of 70 MTC patients with elevated serum Ct or CEA. In total, doubling times were calculated and the DT of the less favorable marker was used to stratify the patients into the low- and high-risk group with the cut-off value of 2 years. The survival analysis was performed using Cox proportional hazard method. RESULTS: The doubling time < = 2 years of the less-favorable marker had significant prognostic impact for recurrence-free survival, HR = 2.61 (1.43-4.71) and overall survival, HR = 8.99 (3.51-23.04). CONCLUSIONS: The calcitonin and carcinembrional antigen doubling times of less than two years are negative prognostic factors for MTC recurrence-free and total survival in patients with persistent or recurrent disease. They may be used as predictive factors for more intensive search of disease localization in asymptomatic hypercalcitoninemia and for therapy choice in symptomatic disease.
format Text
id pubmed-2987862
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29878622010-11-19 The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report Gawlik, Tomasz d'Amico, Andrea Szpak-Ulczok, Sylwia Skoczylas, Aleksander Gubała, Elżbieta Chorąży, Anna Gorczewski, Kamil Włoch, Jan Jarząb, Barbara Thyroid Res Research INTRODUCTION: Calcitonin (Ct) and carcinoembrional antigen (CEA) are widely used as tumor markers for the post-operative follow-up of patients with medullary thyroid carcinoma (MTC). In patients with elevated serum Ct and CEA their dynamics can be described by calculating the doubling time (DT) - the time, they need to double the serum concentration. Previous reports concluded that the Ct and CEA DT have prognostic value in MTC patients. PATIENTS AND METHODS: We retrospectively analyzed data of 70 MTC patients with elevated serum Ct or CEA. In total, doubling times were calculated and the DT of the less favorable marker was used to stratify the patients into the low- and high-risk group with the cut-off value of 2 years. The survival analysis was performed using Cox proportional hazard method. RESULTS: The doubling time < = 2 years of the less-favorable marker had significant prognostic impact for recurrence-free survival, HR = 2.61 (1.43-4.71) and overall survival, HR = 8.99 (3.51-23.04). CONCLUSIONS: The calcitonin and carcinembrional antigen doubling times of less than two years are negative prognostic factors for MTC recurrence-free and total survival in patients with persistent or recurrent disease. They may be used as predictive factors for more intensive search of disease localization in asymptomatic hypercalcitoninemia and for therapy choice in symptomatic disease. BioMed Central 2010-11-03 /pmc/articles/PMC2987862/ /pubmed/21047422 http://dx.doi.org/10.1186/1756-6614-3-10 Text en Copyright ©2010 Gawlik et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Gawlik, Tomasz
d'Amico, Andrea
Szpak-Ulczok, Sylwia
Skoczylas, Aleksander
Gubała, Elżbieta
Chorąży, Anna
Gorczewski, Kamil
Włoch, Jan
Jarząb, Barbara
The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
title The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
title_full The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
title_fullStr The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
title_full_unstemmed The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
title_short The prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
title_sort prognostic value of tumor markers doubling times in medullary thyroid carcinoma - preliminary report
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2987862/
https://www.ncbi.nlm.nih.gov/pubmed/21047422
http://dx.doi.org/10.1186/1756-6614-3-10
work_keys_str_mv AT gawliktomasz theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT damicoandrea theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT szpakulczoksylwia theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT skoczylasaleksander theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT gubałaelzbieta theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT chorazyanna theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT gorczewskikamil theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT włochjan theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT jarzabbarbara theprognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT gawliktomasz prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT damicoandrea prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT szpakulczoksylwia prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT skoczylasaleksander prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT gubałaelzbieta prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT chorazyanna prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT gorczewskikamil prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT włochjan prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport
AT jarzabbarbara prognosticvalueoftumormarkersdoublingtimesinmedullarythyroidcarcinomapreliminaryreport